SARS-CoV-2 N Protein Human Monoclonal Antibody [Clone ID: CR3009 (03-009)]

CAT#: TA386447

Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))

Specifications

Product Data

• Clone Name: CR3009 (03-009)
• Applications: ELISA, IF
• Reactivities: SARS-CoV
• Host: Human
• Isotype: IgM, kappa
• Clonality: Monoclonal
• Immunogen: The original antibody was generated by cloning the variable regions of the scFvs selected from phage display libraries into separate vectors for IgG1 heavy-chain and light-chain expression. The harvested supernatents were then purified on protein A columns. The original antigen was the whole irradiated virion.
• Specificity: This antibody recognizes and binds the non-linear/conformational epitope of the N protein of SARS CoV and also binds the SARS CoV2 nucleoprotein.
  
  This antibody is recommended for detection of SARS CoV2 protein N (nucleoprotein). This antibody binds both the nucleocapsid protein of the SARS-CoV and SARS CoV-2 (2019-nCoV). Initial characterization of the antibody for binding to 2019-nCoV was done using ELISA. This antibody shows potential to be used for development of diagnostic assays. Various isotype versions of the antibody namely human IgG1, IgG3, IgM, IgA and the less common IgG2 and IgG4 are available for the investigation of their role in response to SARS CoV2. Competitive ELISA of this antibody with CR3018 suggests that both these antibodies bind different epitopes of the N protein of SARS CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Immunofluorescence staining was used to demonstrate binding of CR3009 to SARS-CoV infected Vero cells. (PMID:15650189)
• Formulation: PBS with 0.02% Proclin 300.
• Concentration: lot specific
• Conjugation: Unconjugated
• Storage: Please store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C. Avoid freeze and thaw cycles.
• Stability: 3 years from dispatch.
• Database Link:
  UniProt ID P0DTC9
• Note: This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.